SecBot SecBot
SECBOTREPLAY Home › Report › NSPR

NSPR · InspireMD received FDA approval for its CGuard Prime TransCarotid Stent…

InspireMD Inc. · PRESS-RELEASE filed Nov 12, 2026 at 16:01 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Nov 12, 2026 at 16:01 ET

InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in TCAR procedures, doubling the platform's U.S. addressable market to ~75,000 annual carotid stenting procedures. The approval was supported by the CGUARDIANS II trial showing 100% acute device success and zero adverse events at 30 days. This is a significant commercial milestone for the company, which has a $36M market cap and had been limited to CAS procedures.

  • FDA approved PMA Supplement for CGuard Prime TransCarotid Stent System for TCAR procedures
  • Approval doubles total addressable U.S. market to ~75,000 annual carotid stenting procedures (TCAR + CAS)
  • CGUARDIANS II trial: 100% acute device success, zero deaths/strokes/MI/stent thrombosis at 30 days
  • Over 35,000 TCAR procedures performed annually in the U.S.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access